MVC and NIH Collaborate to Develop COVID-19 Vaccine
On February 16th, Medigen Vaccine Biologics Corp. (MVC) and National Institutes of Health (NIH) entered a collaboration agreement. MVC will obtain NIH’s COVID-19 vaccine and related biological materials to conduct animal studies in Taiwa. MVC will, base on the data from animal studies, evaluate the feasibility of human clinical trials.
In response to the outbreak of the novel coronavirus disease in Wuhan, China, MVC actively approached NIH to develop the COVID-19 vaccine candidate for conducting animal studies in Taiwan. MVC aims to speed up the launch of COVID-19 vaccines and enhance domestic capabilities of epidemic prevention.
【About Medigen Vaccine Biologics Corp., MVC】
MVC is a cell-based biopharmaceutical company focusing on the development and production of vaccines and biologics. MVC’s business partners include US NIH, US CDC, WHO/UCAB, Taiwan CDC, and Taiwan National Health Research Institute. MVC’s pipeline includes enterovirus A71 vaccine, dengue vaccine, influenza quadrivalent vaccine which all entered late clinical stage.
【About National Institutes of Health (NIH)】
The National Institutes of Health is the world's top research institution in the field of biomedicine and its annual budget of R & D is nearly US $ 40 billion. NIH has developed the platform of coronavirus vaccines for many years and has successfully selected COVID-19 vaccine candidate. MVC has collaborated with NIH for vaccine development on Dengue vaccines since 2015.